Literature DB >> 8965196

Cocaine congeners as PET imaging probes for dopamine terminals.

A L Brownell1, D R Elmaleh, P C Meltzer, T M Shoup, G L Brownell, A J Fischman, B K Madras.   

Abstract

UNLABELLED: The PET imaging properties of three phenyltropane drugs with differing affinities and selectivities for the dopamine over serotonin transporter, were compared.
METHODS: Carbon-11-CFT (WIN 35,428, 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane), 11C-CCT (RTI-131, 2 beta-carbomethoxy-3 beta-(4-monochlorophenyl)tropane), and 11C-CDCT (dichloropane, 2 beta-carbomethoxy-3 beta-(3,4-dichlorophenyl)tropane) were evaluated as imaging probes for dopamine neurons in five normal and in two MPTP-treated cynomolgus monkeys (macaca fascicularis) using a high-resolution PET imaging system (PCR-I).
RESULTS: For 11C-CFT, the specific binding ratio (as defined by the ratio of radioactivity levels in striatum versus cerebellum) was 4.2 +/- 0.8 in caudate and 4.9 +/- 1.2 in putamen at 60 min and 4.9 +/- 1.2 and 5.5 +/- 1.1 at 90 min in control animals. In MPTP-treated monkeys the corresponding ratios were 1.4 +/- 0.1 in caudate and 1.5 +/- 0.1 in putamen at 60 min and 1.3 +/- 0.1 in caudate and 1.4 +/- 0.3 in putamen at 90 min. For the monochloro analog of CFT, 11C-CCT, the ratios in control caudate and putamen were 2.7 +/- 0.4 and 3.4 +/- 0.3, respectively, at 60 min and 3.7 +/- 0.5 and 4.4 +/- 0.6, respectively, at 90 min. In MPTP-treated animals, corresponding ratios were 1.4 +/- 0.4 and 1.5 +/- 0.3 at 60 min and 1.4 +/- 0.4 and 1.6 +/- 0.4 at 90 min. The dichloro analog of CFT, CDCT, which has the highest affinity for the dopamine transporter, generated the lowest ratios in control brains, 2.3 +/- 0.4 in caudate and 2.4 +/- 0.5 in putamen at 60 min. In one MPTP-treated monkey, the corresponding ratios were 1.6 +/- 0.4 and 1.8 +/- 0.3. In comparison with 11C-CFT, both 11C-CCT and 11C-CDCT were less selective and had high uptake in the thalamus.
CONCLUSION: The present results clearly indicate that 11C-CFT is a useful ligand for monitoring dopamine neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965196

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.

Authors:  V Villemagne; J Yuan; D F Wong; R F Dannals; G Hatzidimitriou; W B Mathews; H T Ravert; J Musachio; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

3.  Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.

Authors:  Christopher A Brown; Morvarid K Karimi; LinLin Tian; Hugh Flores; Yi Su; Samer D Tabbal; Susan K Loftin; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-09-16       Impact factor: 10.422

4.  Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration.

Authors:  Bruce G Jenkins; Aijun Zhu; Pekka Poutiainen; Ji-Kyung Choi; Kun-Eek Kil; Zhaoda Zhang; Darshini Kuruppu; Nurgul Aytan; Alpaslan Dedeoglu; Anna-Liisa Brownell
Journal:  Neuropharmacology       Date:  2015-11-12       Impact factor: 5.250

Review 5.  Recent advances in PET imaging for evaluation of Parkinson's disease.

Authors:  Chrissa Sioka; Andreas Fotopoulos; Athanassios P Kyritsis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

6.  Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Authors:  Bruce G Jenkins; Rosario Sanchez-Pernaute; Anna-Liisa Brownell; Yin-Ching Iris Chen; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.709

7.  Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.

Authors:  Donglang Jiang; Xiuhong Lu; Zijing Li; Nicklas Rydberg; Chuantao Zuo; Fangyu Peng; Fengchun Hua; Yihui Guan; Fang Xie
Journal:  Front Neurosci       Date:  2019-01-15       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.